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Prostate cancer is an androgen receptor (AR)-dependent malignancy at initiation and pro-
gression, therefore hormone therapy is the primary line of systemic treatment. Despite
initial disease regression, tumours inevitably recur and progress to an advanced
castration-resistant state a major feature of which is metastasis to the bone. Up-
regulation of AR cofactors and chaperones that overcome low hormone conditions to
maintain basal AR activity has been postulated as a mechanism of therapy relapse.
p23, an essential component of the apo-AR complex, acts also after ligand binding to in-
crease AR transcriptional activity and target gene expression, partly by increasing
chromatin-loaded holo-receptor-complexes. Immunohistochemical studies have demon-
strated increased p23 expression in advanced prostate cancer. Here, we further character-
ise p23 roles in AR signalling and show that it modulates cytosolic AR levels in the absence
of hormone, confirming a chaperoning function in the aporeceptor complex and suggesting
p23 upregulates AR signalling at multiple stages. Moreover, p23 protein levels significantly
increased upon treatment with not only androgen but also clinically relevant anti-
androgens. This was in contrast to the HSP90 inhibitor 17-AAG, which did not modulate
expression of the cochaperone e important given the HSP90-independent roles we and
others have previously described for p23.
Further, we demonstrate p23 is implicated in prostate cancer cell motility and in acquisi-
tion of invasiveness capacity through the expression of specific genes known to partici-
pate in cancer progression. This may drive metastatic processes in vivo since analysis of
prostate tumour biopsies revealed that high nuclear p23 significantly correlated withry & Cancer, ICTEM, Imperial College London, London W12 0NN, UK. Tel.: þ44 207 5941685;
l.ac.uk (C.L. Bevan).
en University, Sylviusweg 72, 2333 BE Leiden, The Netherlands.
nces, University of Essex, Colchester CO4 3SQ, UK.
4
on behalf of Federation of European Biochemical Societies.
M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 2 9 5e3 0 8296shorter survival times and with development of metastases in patients with lower grade
tumours. We propose that increased p23 expression may allow cells to acquire a more
aggressive phenotype, contributing to disease progression, and that p23 is a plausible sec-
ondary target in combination with HSP90 inhibition as a potential therapy for advanced
prostate cancer.
ª 2014 Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.1. Introduction transcriptional activity to a similar extent as observed for3 Non-standard abbreviations: AR, androgen receptor; ER, oes-
trogen receptor; HSP90, heat shock protein 90; EMT, epithelial to
mesenchymal transition; DOX, doxycycline; Mib, mibolerone.The molecular chaperone p23 is ubiquitously expressed and
highly conserved from yeast to humans (Felts and Toft, 2003;
Garcia-Ranea et al., 2002). It was first characterised as a
component of the progesterone receptor (PR) complex but is
an intrinsic component of several other steroid receptor (SR)
hetero-complexes, exerting distinct effects on different recep-
tors (Freeman and Yamamoto, 2002; Hutchison et al., 1995;
Nair et al., 1996; Reebye et al., 2012). For instance, p23 has
been shown to decrease glucocorticoid receptor (GR) activity
by disassembling receptor hetero-complexes from chromatin,
but to increase activity of the androgen and oestrogen recep-
tors (AR and ER) (Freeman and Yamamoto, 2002; Knoblauch
and Garabedian, 1999; Oxelmark et al., 2006; Reebye et al.,
2012). Encoded by the PTGES3 gene, p23 is an acidic 160 amino
acid protein that can be divided into two domains, an amino-
terminal region containing an HSP90 binding site (residues
86e108) and an unstructured carboxyl terminal domain (Ali
et al., 2006; Martinez-Yamout et al., 2006; Weikl et al., 1999;
Zhu and Tytgat, 2004). p23 is the smallest component of the
HSP90 chaperone machinery, with a molecular weight of
23,000 Da, and is mainly known for binding the ATP-bound
form of HSP90, inhibiting its intrinsic hydrolytic activity and
stabilising several HSP90-substrate complexes including Fes
tyrosine kinase, transcription factors such as HSF1, telome-
rase and the reverse transcriptase enzyme (Holt et al., 1999;
Hu et al., 2002; Nair et al., 1996). Further highlighting the
importance of p23 in cellular function and development, a
knockout mouse model exhibited prenatal or perinatal
lethality and p23 has also been shown to possess prosta-
glandin E2 synthase activity, although the significance of
this remains unclear since p23 knockout mice do not exhibit
impaired prostaglandin enzymatic activity (Felts and Toft,
2003; Grad et al., 2006; Lovgren et al., 2007; Tanioka et al., 2000).
Although p23 has historically been studied as an HSP90 co-
chaperone, a number of studies published over recent years
suggest it also exerts some of its functions in an HSP90-
independent manner. Several groups have demonstrated
that p23 can continue acting on proteins that have been
released from HSP90 and p23 has also been shown to possess
a passive, ATP-independent chaperoning activity in the C-ter-
minus and suppress the aggregation of denatured proteins
(Bose et al., 1996; Freeman et al., 2000, 1996; Freeman and
Yamamoto, 2002; Reebye et al., 2012). Our laboratory has
shown that the interaction between p23 and AR is at least
partially HSP90-independent and that a mutant form of p23
unable to bind HSP90 significantly enhanced ARwild type p23 (Reebye et al., 2012).3
There is considerable evidence that p23 could be impli-
cated in cancer processes as it has been shown to be up-
regulated in several tumour types, including lung, prostate
and breast as well as acute lymphoblastic leukaemia (Elmore
et al., 2008; Krebs et al., 2002; Li et al., 2009; Liu et al., 2012;
Mollerup et al., 2003; Oxelmark et al., 2006; Reebye et al.,
2012). The role of p23 in breast cancer has been extensively
studied by the Garabedian laboratory, who showed p23 en-
hances cell motility and that higher levels correlate with
poor prognosis and a reduction in disease-free survival time
in breast cancer patients (Oxelmark et al., 2006; Simpson
et al., 2012, 2010). We have previously shown nuclear p23 to
enhance AR activity and binding to chromatin, critical steps
for AR signalling and prostate cancer development, and to
be increased with tumour grade (Reebye et al., 2012). Similarly
to what has been described in breast cancer, here we show
that p23 also affects prostate cancer cell migration and inva-
sion properties without affecting cell growth. Moreover, p23
may mediate these effects by selectively modulating the
expression of genes previously involved in metastatic pro-
cesses. Supporting clinical significance, nuclear p23 correlates
with a decrease in survival in patients with Gleason score 7
and with an increase in metastatic progression.
Prostate cancer is, in its early stages, an AR-dependentma-
lignancy and non-curative treatments, such as anti-
androgens, are designed to inhibit AR signalling. Despite
high initial success, therapeutic failure very frequently occurs
and the malignancy progresses to a hormone-refractory stage
for which no effective treatment has been yet developed.
HSP90 inhibitors such as geldanamycin and synthetic deriva-
tives e.g. 17-AAG are now in clinical trials for prostate cancer.
These drugs inhibit HSP90 largely by preventing its interaction
with p23. However, the yeast p23 homologue, Sba1, was
shown to protect cells against the effects of HSP90 inhibitors
such as geldanamycin or radicicol (Forafonov et al., 2008)
and here we show that both androgen and antiandrogens
can increase p23 protein levels. In combination with our ob-
servations regarding the positive effects of p23 upon AR stabi-
lisation and signalling, and also on cell aggressiveness and
motility, this leads us to postulate that inhibiting p23 in com-
bination with HSP90 could be an effective therapeutic combi-
nation against prostate cancer.
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2.1. Cell culture
LNCaP, C4-2 and PC-3 cells were cultured in RPMI-1640 (Sigma)
supplemented with 100 U/ml penicillin, 0.1 mg/ml strepto-
mycin, 2 mmol/L glutamine (Sigma) and 10% fetal bovine
serum (Labtech International, Ringmer, East Sussex, UK).
LNCaP-TR2-MAR4-p23-V5 cells (referred to as LNCaP-p23
throughout) (Reebye et al., 2012) were grown as above but us-
ing certified tetracycline-free-medium (Firstlink UK, Sheffield,
UK).
2.2. Time courses
LNCaP cells were cultured in 6-well plates at a density of
4  105 cells/well in hormone-depleted medium, comprising
phenol red-free RPMI (Sigma) supplemented as above but
with 5% charcoal-stripped fetal bovine serum (Labtech Inter-
national), for 72 h prior to treatment with 10 nM mibolerone
(Mib) (PerkinElmer Life Sciences, Wellesley, MA), 1 mM bicalu-
tamide (Bic) (Sigma, Chemical Co., St. Louis, MO) or 10 nM 17-
allylamino-17-demethoxygeldanamycin (17-AAG) (Sigma).
Cells were harvested for protein extraction and protein
expression assessed by Western blotting using 10 mg of total
lysate.
2.3. Immunoblotting
Equal amounts of total protein were separated by SDS-PAGE,
transferred onto PVDF membrane (Millipore, Watford, UK)
and probed using primary antibodies: mouse anti-p23
(1:3000, ab2814, Abcam), rabbit anti-AR (AR441, 1:1000,
Dako), rabbit anti-HSP90 (sc7977, 1:500, SantaCruz), mouse
anti-b-actin (ab8226, 1:8000, Abcam), mouse anti-atubulin
(DM1A, 1:1000, Sigma) and mouse anti-vinculin (V9131,
1:1000, Sigma). Proteins were detected using horseradish
peroxidise-conjugated anti-mouse or anti-rabbit secondary
antibodies (1:2000, DAKO) and visualised using the ECL system
(GE Healthcare).
2.4. RNA preparation and quantitative real-time PCR
Total RNAwas extracted using the RNeasy extraction kit (QIA-
GEN, Chatsworth, CA) and 500 ng RNA reverse transcribed us-
ing the reverse transcriptase kit (PrimerDesign). LAMB1,
KYNU, CTSD and PMP22 expressionwas assessed by quantita-
tive real-time PCR using Fast Reaction SYBR-Green mixture
(Applied Biosystems). Data were normalized to GAPDH
expression. Primer sequences are shown in Supplemental
Table S1.
2.5. Transient knockdowns
LNCaP cells were grown to 70% confluence in 6-well plates,
transferred to starvation medium for 24 h before transfection
with 100 nM/well p23-targeting small interfering RNA(siRNA)
pool (Dharmafect L-004496e00; Dharmacon, Lafayette,CO) or
scrambled negative control using 2 ml of Dharma-FECT-2transfection reagent (Dharmacon). Cells were harvested for
protein extraction 72, 96 and 120 h after transfection and pro-
tein expression was assessed by Western blotting using10 mg
of protein lysate. For AR knockdown experiments, LNCaP-
AR-shRNA or LNCaP-AR-scrambled inducible cell lines (kind
gift from Paul Rennie, University of British Columbia, Vancou-
ver, Canada (Cheng et al., 2006)) were treated with 2 mM doxy-
cycline (DOX) for 72, 96 and 120 h prior to being harvested for
protein extraction and Western blotting performed as above.
2.6. Transwell assays
Migration assays were performed in triplicate using Compan-
ion 24-well plates and transwell chambers (both BD Falcon)
with 8 mm pore size membranes previously coated with
100 ml of collagen diluted to 25 mg/ml using serum freemedium
(Invitrogen) for 2 h at room temperature. LNCaP-p23 cells pre-
treated with 100 nM DOX or vehicle control for 48 h, or LNCaP
cells previously transfected with specific siRNA against p23 or
non-targeting siRNA as negative control, were seeded at a
density of 1.5  104 cells/transwell in serum free medium
into the upper chamber of the transwell. The bottom chamber
was filled with 650 ml of RPMI-1640 medium containing 10%
FCS and left at 37 C for 24 h. Invasion assays were performed
as above but the top chamber was also pre-coated with 4 mg/
cm2 of matrigel (BD biosciences) for 3 h prior to cell seeding.
The contents of the upper chamber were then scraped out
and the filter fixed by incubation with 4% PFA for 20 min at
room temperature, stained with crystal violet and washed.
Migration and invasionwere quantified using ImageJ software
and results normalised to the corresponding cell density.
2.7. Wound healing assays
LNCaP cells or PC3 cells were transfected with either siRNA
against p23 or non-targeting siRNA as negative control for
72 h prior to being seeded to confluence in 6-well plates in
full medium. Monolayers were scratched with a pipette tip
and washed with PBS twice to remove cell debris. Cells were
maintained in hormone-depleted medium and imaged by
contrast microscopy (Eclipse, TS100, Nikon). Images were
captured at the time and 24, 36 and 48 h after scratching, or
every 30 min up to 12 h for PC3 cells.
2.8. Proliferation assays
LNCaP cells previously transfected with siRNA p23 or a non-
targeting control, and LNCaP-p23 cells treated with 100 nM
DOX to enhance p23 expression or vehicle control, were
seeded in 96-well plates at a density of 1  104 cells/well in
full medium. Cell viability was assessed by incubation with
20 ml of the MTS reagent (Promega) for 2 h at 37 C following
manufacturer’s instructions. Crystal violet assays were also
performed and for this LNCaP cells were seeded in 96 well-
plates at a density of 2000 cells/well in full medium. Twenty-
four hours after seeding, cells were treated with 0.1, 0.5, 2.5,
5 or 10 mM 17-AAG or DMSO as vehicle control for 16, 24, 48
and 72 h. After this time cells were fixed with 4% PFA, washed
twice in PBS and stained with 0.8% crystal violet for 30 min at
room temperature. Cells were then washed four times with
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lubilised in 100 ml 10% acetic acid and absorbance read at
595 nm.
2.9. Tissue microarray and immunohistochemistry
Immunohistochemistry was performed using 3 tissue micro-
arrays (TMAs) of benign and malignant prostate biopsies
derived from transrectal biopsy, transurethral resection, and
radical prostatectomy as previously described (Brooke et al.,
2011; Gaughan et al., 2011). All materials were used in accor-
dance with approval granted by the Northumberland, Tyne
and Wear NHS Strategic Health Authority Research Ethics
Committee (reference 2003/11; The Freeman Hospital). The
final study included 321 cancer biopsies and 69 benign bi-
opsies. Antigen retrieval was achieved by immersion in
10 mmol/L citric acid buffer (pH 6.0), followed bymicrowaving
for 15 min (at 1000 W) in a pressure cooker. Sections were
immunostained with a mouse monoclonal antibody against
p23 (Abcam) on a DAKO autostainer using Vectastain ABC
kits (Vector Labs), according to the manufacturer’s protocol.
Sections known to stain positively were included in each
batch, and negative controls were prepared by replacing the
primary antibody with TBS buffer. p23 expression was scored
blindly for epithelial nuclear intensity of staining and number
of epithelial nuclei positive per field, in each biopsy core.
Slides were scanned using a Scanscope GL scanner (Aperio)
and analysed using SpectrumTM software (Aperio). For statis-
tical analysis, samples were split into low or high intensity/
number of positive nuclei (low ¼ 0, 1 and high ¼ 2, 3).3. Results
3.1. Altering p23 levels affects AR stabilisation in the
absence of ligand
We have previously shown that increasing levels of p23 by
ectopic expression significantly enhances AR transcriptional
activity and, conversely, decreasing p23 levels using siRNA de-
creases it (Reebye et al., 2012). To further clarify the roles p23
may play within the AR signalling pathway, the effects of p23
over-expression or knockdown upon AR protein levels were
analysed under hormone-depleted conditions. For this pur-
pose we ectopically expressed V5-tagged p23 using the
LNCaP-p23 cell line by incubating with 100 nM doxycycline
(DOX) for 48 h in full media, to induce ectopic p23 expression,
prior to culturing cells under starvation conditions for the
specified times (Figure 1A). As shown, in the absence of
DOX, AR levels decreased due to the hormone-depleted condi-
tions in which cells were cultured but increasing p23 abro-
gated this effect and levels of AR remained stable. This
stabilisation was only evident under hormone-depleted con-
ditions, since prior to starvation at the 0 h time point no differ-
ences were detected between untreated and DOX-treated
samples.
The converse experiment was also performed and parental
LNCaP cells were transfectedwith siRNA against p23, or a non-
targeting control siRNA, and cells harvested at the specified
time points. In agreement with observations above,decreasing p23 significantly diminished AR protein levels for
all time points analysed (Figure 1B). Together, this suggests
p23 plays a key role in stabilising AR.
3.2. Effects of androgen upon p23 protein levels
Very little is known regarding the mechanisms regulating p23
expression despite the essential roles p23 plays in cell func-
tion.We further examined the regulation of p23 in the context
of AR signalling and prostate cancer by treating LNCaP cells
with 10 nM of the synthetic androgen mibolerone (Mib)
(Figure 2A). From analyses of cell lysates we observed that
whereas addition of Mib had no effect upon HSP90, it caused
a significant increase in p23 levels at and beyond 24 h treat-
ment, suggesting p23 protein could be androgen-stabilised
or induced (Figure 2B). To further clarify the involvement of
androgens and their receptor in p23 regulation, the LNCaP-
AR-shRNA cell line, in which AR knockdown is induced
upon DOX treatment (Cheng et al., 2006), was used to study
the effects of AR on p23 expression. AR knockdown had no ef-
fect upon p23 protein levels since no differences were
observed in DOX-treated cells compared to those treated
with vehicle (Figure 2D) e as a control, no significant changes
in either protein were observed in the control scrambled
shRNA-transfected cell line (Figure 2C).
We also investigated the effects on p23 protein levels after
inhibiting either AR (using the therapeutic anti-androgen
bicalutamide (Bic)) or the HSP90-p23 interaction (using the
HSP90 inhibitor 17-AAG, currently in phase II clinical trials
(Neckers and Workman, 2012)). LNCaP cells were seeded in
starvation medium prior to treatment with 1 mM of Bic
(Figure 2A,B) or 10 nM of 17-AAG (Figure 3A,B). As seen for
Mib, addition of Bic did not have an effect on HSP90 endoge-
nous levels, which remained similar to untreated cells
(Figure 2B). p23 endogenous levels increased over vehicle-
treated up to 24 h after treatment with Bic, although not to
the extent seen for Mib, and stayed constant for the remaining
duration of the experiment (Figure 2B). Contrary to what was
observed for Bic, addition of 17-AAG (which inhibits HSP90
by blocking its interaction with p23) decreased AR to levels
below those obtained for vehicle-treated cells, but did not
significantly affect endogenous p23 levels, and increased
HSP90 levels 72 h after treatment (Figure 3B). Increased
HSP90 levels following treatment with an HSP90 inhibitor
has previously been reported, and attributed to cellular stress
response following HSP90 inhibition (Lamoureux et al., 2011).
Results shown demonstrate p23 can affect AR protein
levels, further confirming its role in the signalling pathway.
Given the effects of p23 upon AR activity (Reebye et al., 2012)
and stability (and vice-versa) and since prostate cancer is an
AR-driven malignancy, we next investigated whether p23
may also be involved in promoting prostate cancer
progression.
3.3. Altering p23 levels does not affect prostate cancer
cell growth
To elucidate whether p23 has a role in cell viability, growth as-
says were performed using the LNCaP-p23 inducible line for
enhanced p23 ectopic expression and parental LNCaP cells
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Figure 1 e p23 regulates AR expression in the absence of hormone. (A) LNCaP-p23 cells were treated with 100 nM doxycycline (DOX) for 48 h
followed by a 48 h hormone-depletion also in the presence of DOX. Cell lysates were collected at the indicated time points, harvested, resolved by
Western blotting and transferred to PVDF membranes, which were probed using specific antibodies against AR, p23 and beactin. Densitometry
was performed on Western Blotting results normalising against signal obtained for beactin. (B) LNCaP cells were transfected with specific siRNA
against p23 collected at the indicated time points, harvested and resolved by Western Blotting. Gels were transferred onto PVDF membranes and
probed with specific antibodies against p23, AR and b-actin. Densitometry performed on Western results as above. Results presented are the
mean ± 1 STDEV of three independent experiments. *p value £0.05 **p value £0.005 ***p value £0.0005 (Student’s t test).
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expression and knockdown were verified by Western blotting
(Figure 4A and B respectively). As shown in Figure 4A, over-
expression of p23 (which in the presence of doxycycline was
increased by around 60%) did not affect cell growth at any of
the time points analysed and no differences were observed
when compared to vehicle-treated cells. Concordantly, the
converse experiment in which p23 was transiently knocked-
down also indicated no changes in cell viability when
compared to the non-targeting transfected control cells
(Figure 4B). The results suggest p23 has no direct role in cell
proliferation.3.4. p23 increases prostate cancer cell motility and
invasiveness
The effects of p23 inmetastasis formation and cancer progres-
sion have been previously studied in breast cancer but the role
of p23 in prostate cancer spread is relatively unexplored
(Oxelmark et al., 2006; Simpson et al., 2012, 2010). We used
transwell assays wherein an FCS gradient was created by add-
ing full medium into the lower chamber and cells allowed to
migrate for 24 h. Increased, ectopic expression of p23 signifi-
cantly increased LNCaP-p23 cell migration (Figure 5A) through
the FCS gradient. Next, wound-healing assayswere performed
Figure 2 e p23 regulation. (A) LNCaP cells were stripped for 72 h prior to treatment with 10 nM mibolerone (Mib) or 1 mM bicalutamide (Bic) for
the indicated time points. Cells were harvested and lysates resolved by Western blotting, transferred onto PVDF and membranes probed with
specific antibodies against HSP90, p23 and aetubulin. (B) Graphs for HSP90 and p23 represent densitometry performed on Western-blot images
for each of the treatments and normalised against the signal obtained for a-tubulin. Mib and Bic treated samples were then normalised against the
corresponding untreated control for each time point, hence vehicle treated results have been removed from graphs for clarity. Results presented are
the mean ± 1 standard error of three experiments. LNCaP cells stably transfected with scrambled (C) or shRNA against AR (D) were treated with
2 mM doxycycline (DOX) for 48 h. Cells were lysed at the indicated time points and proteins resolved by SDS-PAGE and probed with antibodies
against AR, p23 and b-actin. Figures are a representative result of four experimental replicates. Graphs for either the scrambled (C) or shRNA
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Figure 3 e p23, HSP90 and AR expression in response to 17-AAG. (A) LNCaP cells were incubated in hormone-depleted medium for 72 h prior
to treatment with 10 nM of the HSP90 inhibitor 17-AAG. Cells were harvested and lysates resolved by Western blotting, transferred onto PVDF
and membranes probed with specific antibodies against AR, HSP90, p23 and aetubulin. (B) Graphs for HSP90 and p23 represent densitometry
performed on Western-blot images for each of the treatments and normalised against the signal obtained for a-tubulin. Results presented are the
mean ± 1 standard error of three independent experiments. * [ p £ 0.05; ** [ p £ 0.005 (Student’s test).
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 2 9 5e3 0 8 301in LNCaP cells transfected with either siRNA against p23 or a
non-targeting control (Figure 5B). Cells were incubated under
starvation conditions to prevent cell proliferation, the mono-
layer scratched at maximal cell confluency and wound recov-
ery monitored up to 36 h after wounding. The same field was
imaged and wound area quantified for each condition
throughout the time course. Both monolayers initially pre-
sented a very similar degree of confluency and both scratches
were of similar length and width. Although progressive
wound closure was observed in control cells, which colonised
up to 60% of the initial wound area after 36 h, depleting endog-
enous p23 caused a delay in wound recovery with a maximal
recovery of approximately 20%. Together, this data supports a
role for p23 in cell motility and migration. We also performed
wound healing assays in PC3 cells, which do not express func-
tional AR, and found that depletion of p23 by siRNA also signif-
icantly reduced wound recovery i.e. cell motility
(Supplemental Figure 1). This demonstrates that the effects
of p23 on cellmotility aremediated via non-AR client proteins,
although does not rule out involvement of AR in AR-positive
cells.transfected line (D) represent densitometry performed on western results, no
for both C and D. Results presented are the mean ± 1 standard error of fourSince manipulating p23 levels affected cell motility/migra-
tion, we next investigated the effects on cell invasive potential
using LNCaP-p23 and parental LNCaP cells. Cells were treated
as for migration assays but the transwell filter was coated
with a matrigel layer prior to cell seeding. As shown in
Figure 6A, and despite what was previously described for
cell migration assays, p23 over-expression did not signifi-
cantly affect cell invasion, although a small increase in the
number of invading cells was observed upon DOX treatment
(Figure 6A). However, a strong decrease in cell invasion (2.5-
fold) was seen in cells transfected with siRNA against p23
compared to non-targeting -transfected cells (Figure 6B).
This supports a role for endogenous p23 in invasive potential
of prostate cancer cells.
3.5. High p23 expression correlates with decreased
survival and bone metastasis in prostate cancer patients
As prostate cancer cells expressing higher p23 appeared to
have increased invasive potential in our assays, we hypothe-
sized that patients expressing high levels of p23 protein mayrmalising against signal obtained for b-actin. The shading is the same
independent experiments. *[ p £ 0.05; **[ p £ 0.005 (Student’s test).
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Figure 4 e p23 levels do not affect cell growth. (A) LNCaP_p23 cells were treated with 100 nM doxycycline (DOX) for 48 h prior to seeding in 96-
well plates for cell viability assessment. Twenty microlitres of MTT reagent was added to each well, incubated for 2 h at 37 C and absorbance
measured at 490 nm at the specified time points. To verify p23 ectopic expression, cells were treated as above and lysates collected, harvested and
resolved by Western blotting. Gels were transferred onto nitrocellulose membranes and probed with specific antibodies against p23 and b-actin.
(B) LNCaP cells were transfected with individual siRNAs against p23 or a scrambled control for 72 h prior to seeding in 96-well plates for cell
viability assessment, performed as in (A). To verify p23 knockdown cells were transfected and collected at the indicated time points. Lysates were
resolved by SDS-PAGE, transferred onto nitrocellulose membranes and probed with specific antibodies against p23 and b-actin. Results are the
mean ± 1 STDEV of two independent experiments performed in triplicate.
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quently have shorter survival times. To investigate this,
immunohistochemistry was performed on prostate cancer
tissue microarrays and specimens scored for primary Gleason
grade and for nuclear and cytoplasmic p23 staining on a scale
of 0e3 (3 ¼ highest intensity). An inverse correlation between
nuclear p23 expression and patient survival was observed. Pa-
tients with high nuclear p23 expression showed significantly
shorter overall survival, with mean survival decreasing from
67 to 40.2 months and median from 57.4 to 31.7 months
(Figure 7A and Table 1, p value ¼ 0.017). Disease-specific sur-
vival was also decreased in patients with high nuclear p23,
with mean survival decreasing from 90.2 to 52.3 months
(Supplemental Figure 2A and Supplemental Table S2). The
survival differences were more significant in patients with
lower grade tumours (Gleason grade 7, data not shown).
Even in patients with confirmed metastatic lesions, there
was a significant difference in survival between patients
with high and low p23 (Figure 7B); reduction in survival was
significantly correlated with high p23 nuclear expression sug-
gesting p23 could serve as a poor prognostic indicator.
In agreement with our in vitro data, a direct correlation be-
tween the development of metastatic lesions and p23 nuclearlevels was observed although this was only significant in pa-
tients with Gleason score 7 (Figure 7C). No significant differ-
ences were observed when analysing p23 cytoplasmic
staining, further highlighting a role for nuclear p23 in prostate
cancer progression.
3.6. Increased p23 levels cause changes in gene
expression associated with invasive malignancies
To unravel the mechanism by which p23 affects cell motility,
the protein expression levels of a panel of epithelial-to-
mesenchymal transition (EMT) markers (snail, E-cadherin,
vimentin, becatenin) was analysed in the inducible LNCaP-
p23 line. No changes in any of the markers analysed were
observed despite increased V5-p23 expression, suggesting
p23 does not exert its effects upon cell motility in this manner
(Figure 8A). However vinculin, a component of focal adhe-
sions, was significantly increased (1.4 fold) in cells ectopically
expressing p23, supporting previous observations that knock-
ing down p23 reduces vinculin levels (Echtenkamp et al., 2011)
and suggesting p23 may alter cell motility via modulating the
interaction between the plasma membrane and the actin
cytoskeleton.
Figure 5 e p23 levels affect cell migration. (A) LNCaP_p23 cells were treated with 100 nM doxycycline (DOX) for 48 h prior to seeding at a density
of 1.53 104 in serum free medium in the upper chamber of transwells pre-coated with collagen for 2 h. Full media was placed in the lower chamber
and used as a chemoattractant. After 24 h, cells in the lower chamber were fixed, stained and migration quantified using ImageJ. To verify p23
ectopic expression cells were harvested and lysates resolved by Western Blotting and probed with specific antibodies against p23 and b-actin.
Results are the mean ± 1 STDEV of a representative experiment performed in triplicate. (B) LNCaP cells were transfected with siRNA against p23
or non-targeting control. Seventy-two hours after cells were seeded to confluency in a 6-well plate and 24 h after monolayers were scratched with a
pipette tip, washed with PBS twice and incubated in hormone-depleted media for further 36 h. Recovery of the wound was monitored and images
were taken at the specified time points after scratching. The wound area was measured for each time point and condition using ImageJ and values
were made relative to the corresponding wound at 0 h and expressed as a percentage. C4-2.
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cer cells, p23 modulates the expression of a set of genes dys-
regulated in advanced breast cancer including those
involved in migration, invasion, metabolism or transcrip-
tional regulation (Simpson et al., 2012, 2010). To verify
whether a similar mechanism could be responsible for p23 ef-
fects upon prostate cancer cell motility, the expression of the
top p23-regulated genes observed in themicroarray studywas
analysed in our LNCaP-p23 cells. We found that DOX treat-
ment, i.e. increased p23 expression, significantly altered the
expression of several such genes (Figure 8B) suggesting p23
may act by reprogramming gene expression profiles into
more aggressive phenotypes. KYNU, CTSD and PMP22 are
known to be up-regulated in advanced metastatic cancers
and correlate with poor prognosis whereas LAMB1 encodes a
laminin-1 protein shown to have reduced expression in breast
cancer (Minn et al., 2005; Pruitt et al., 2013; Simpson et al.,
2010; Tong et al., 2010).4. Discussion
p23 is a molecular chaperone best characterised as an HSP90
co-chaperone responsible for inhibiting the ATPase activity
of the HSP. Less is known regarding other roles for p23,although it is important in several cellular processes,
including modulating the activity of SRs such as AR, ER, GR
and PR (Freeman and Yamamoto, 2002; Knoblauch and
Garabedian, 1999; Reebye et al., 2012). We previously demon-
strated that p23 enhances AR transcriptional activity and
DNA-binding. We now describe that p23 appears to be also
important in stabilising AR in the absence of hormone since
modulating levels of p23 protein resulted in changes in AR
levels. Ectopically enhanced expression of p23 resulted in
increased AR levels in the absence of hormone, which could
be due to stabilisation/prevention of degradation of unli-
ganded AR in the cytoplasm. Conversely, transient p23 knock-
down significantly increased AR protein turnover. We have
thus demonstrated the prominent role of p23 in foldosome
complex function, as altering p23 levels alone without
affecting the major component of this complex, HSP90, is suf-
ficient to significantly affect AR. Importantly, this occurred in
the absence of androgens, whichmimics the situation in pros-
tate cancer patients undergoing androgen deprivation ther-
apy. The mechanism by which this occurs remains to be
elucidated although it is likely to involve the previously
demonstrated direct interaction between AR and p23
(Reebye et al., 2012), or could be via modulation of the HSP90
ATPase activity, which would in turn result in a stabilisation
of the mature form of the SR heterocomplex. It is unlikely
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Figure 6 e p23 increases cell motility. (A) LNCaP_p23 cells were treated as per Figure 5 and (B) LNCaP cells were transfected with siRNA against
p23 or a scrambled control for 72 h prior to being seeded at a density of 1.5 3 104 in serum free medium in the upper chamber of transwells pre-
coated with collagen for 2 h and matrigel for further 2 h. Full media was placed in the lower chamber and used as a chemoattractant. After 24 h,
cells in the lower chamber were fixed, stained and invasion quantified using ImageJ. To verify p23 overexpression (A) and knockdown (B) cells were
harvested 72 h after transfection and lysates resolved by Western Blotting and probed with specific antibodies as indicated. Results are the
mean ± 1 STDEV of a representative experiment performed in triplicate *p value £0.05 (Student’s t test).
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not been described to bind any regulatory regions in the vicin-
ity of the AR gene (Massie and Mills, 2011; Sharma et al., 2013)
and addition of Mib did not significantly alter p23 gene expres-
sion (Supplementary Figure S2). A similar mechanism has
been described for HSP27, knockdown of which has been
shown to promote AR degradation through the proteasome
pathway while AR mRNA remained unchanged (Zoubeidi
et al., 2007).
Althoughmetastasis (usually to the bone) is themost lethal
development of prostate cancer, very little is known about the
mechanisms involved. We have provided evidence that p23
may be implicated in driving prostate cancer progression
and metastasis although no effects on prostate cancer cell
growth/viability were observed upon manipulation of p23
levels. Our results support previous reports by Oxelmark
et al. which showed, in a breast cancer model, that p23 over-
expression neither affected MCF-7 cell growth nor enhanced
the expression of growth-related genes, despite increasing
transcription of other ER target genes (Oxelmark et al., 2006).
In our studies, p23 over-expression significantly enhanced
cell migration while p23 knockdown decreased cell motility
and invasiveness potential. While increasing p23 levels did in-
crease invasiveness this was not significant, suggesting that
p23 is required but not limiting for this process. p23 has
been already shown to enhance MCF-7 cell invasion andadhesion, thus potentially facilitating tumour invasion in
breast, and our findings confirm a role for p23 as a regulator
of events associated with these processes in prostate cancer
cells (Oxelmark et al., 2006; Simpson et al., 2010). Further sup-
porting this possible role of p23, ectopic expression of the
chaperone enhances vinculin expression, which is implicated
in the epithelial to mesenchymal transition (EMT) and tumour
spreading. Conversely, p23/MEFs present a vinculin impair-
ment (Echtenkamp et al., 2011), strongly suggesting involve-
ment of p23 in driving tumour cells towards high invasion
profiles via modulating some EMT-dependent cellular
changes and interactions within cytoskeleton components.
HSP90 has also been implicated in cell motility andmetastatic
processes since HSP90 over-expression enhanced wound re-
covery (Tsutsumi and Neckers, 2007). Moreover, HSP90 also
promotes activation of extra-cellular proteins such as MMP-
2, leading to enhanced tumour invasiveness (Eustace et al.,
2004; Stellas et al., 2010). Given the interactions between p23
and HSP90 and the fact that p23 as well as HSP90 has been
found in conditioned media of fibrosarcoma cells (Eustace
and Jay, 2004), it is plausible to infer that p23 is also indirectly
involved in these processes through its role as an HSP90 co-
chaperone. Concomitantly, immunostaining performed on
prostate cancer biopsies showed an association between
eventual development of metastatic lesions with high nuclear
p23 expression in tumours graded Gleason 7 at diagnosis.
Figure 7 e p23 expression directly correlates with patient survival and disease progression. Immunohistochemistry was performed on human
prostate cancer tissue microarrays and cores scored for intensity of nuclear and cytoplasmic p23 staining. (A) Kaplan Meier graph depicting relation
between overall survival and p23 nuclear staining in prostate cancer patients (n[ 53). Low[ score 0 or 1, High[ score 2 or 3. (B) Kaplan Meier
graph depicting relation between overall survival and p23 nuclear staining in prostate cancer patients with confirmed metastatic disease (n[ 31).
(C) Correlation between the intensity of nuclear and cytoplasmic p23 expression with the development of metastatic lesions in prostate cancer
patients with Gleason score £7. *p value £0.05 (one-tailed Student’s t test).
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tor, to assess the likeliness of developingmetastatic lesions in
patients with low Gleason stage tumours. There is a clinical
need to stratify such patients for metastatic risk as early as
possible, to target aggressive treatment to patients who will
benefit and avoid overtreatment of others. Moreover, and
further confirming a role for p23 in driving metastatic pro-
cesses, we have reported that over-expression of p23 is suffi-
cient to cause some reprogramming of gene transcription
into a potentially more aggressive phenotype. This is in agree-
ment with previous findings reported in breast cancer cells,
suggesting that the pathway by which p23 acts upon gene
expression is conserved across different tissues and cell types,
and is not dependent upon AR (Echtenkamp et al., 2011;
Simpson et al., 2010).
The chaperoning complex is a potentially important thera-
peutic target in advanced prostate cancer, given the signifi-
cance of HSP client proteins including growth factors and
the AR (Ischia et al., 2013). Reducing p23 levels impacted
upon cell proliferation, motility and migration, and this
included reducingmotility of AR-negative cells. This is consis-
tent with the effects being mediated through other HSP90
client proteins or co-chaperones but does not rule out some
contribution of AR, which has previously been described byother groups (Castoria et al., 2011, 2003; Niu et al., 2008). Given
that we have previously demonstrated a p23 interaction with
AR, and that nuclear translocation and enhancement of AR ac-
tivity are partially HSP90-independent, we postulate that
selectively inhibiting p23 in combination with HSP90 could
be a more efficient therapeutic strategy than HSP90 inhibition
alone. This is supported by the fact that analysis of prostate
cancer tissue microarrays highlighted a correlation between
high nuclear levels of p23 and shorter overall and disease-
specific survival times. In further support of this, analysis of
the transcriptomic profiles of a publically available dataset
(Taylor et al., 2010) of prostate cancer (http://www.ncbi.nlm.-
nih.gov/geo/query/acc.cgi?acc¼GSE21034) shows high p23
expression in prostate tumours correlated with decreased
overall survival (Supplementary Figure S2B).
In conclusion, we have provided evidence supporting a role
of p23 and HSP90 in AR signalling and disease progression
involving the acquisition of increased cell motility and inva-
siveness potential, which appears to translate to the clinical
scenario whereby high nuclear p23 is associated with and
may drive increased occurrence of metastasis. Data presented
here suggests HSP90 and p23 are involved in driving these
cellular processes, further supporting these proteins as valid
therapeutic targets in prostate cancer, and in the case of p23
Table 1 e Correlation of p23 staining with overall survival in prostate cancer patients. The intensity of nuclear p23 staining was correlated with
patient data and median and mean overall survival times in prostate cancer patients were calculated.
Nuclear intensity Overall survival time (months)
Meana Median
Estimate SE 95% CI Estimate SE 95% CI
Lower bound Upper bound Lower bound Upper bound
Low 66.968 7.604 52.064 81.873 57.400 18.791 20.569 94.231
High 40.205 6.421 27.619 52.791 31.700 2.768 26.274 37.126
Overall 56.600 5.599 45.625 67.575 43.200 9.583 24.417 61.983
a Estimation is limited to the largest survival time if it is censored.
Figure 8 e p23 specifically alters the expression of EMT components and re-programmes chromatin transcription towards a more metastatic profile.
(A) p23-V5 tagged ectopic expression was induced in LNCaP-p23 cells as explained before prior to cells being harvested and 10 mg of total lysate
resolved by SDS-PAGE, transferred onto nitrocellulose membranes and probed with specific antibodies against vinculin, V5 and a-tubulin. Signal
was quantified using ImageJ and normalised against the corresponding loading control. Results are the mean of 3 independent experiments. (B)
LNCaP_p23 cells were incubated with or without DOX for 10 days prior to being harvested for RNA extraction. 500 ng of RNA were reverse-
transcribed and qRT-PCR performed using specific primers against LAMB1, KYNU, CTSD and PMP22 genes. GAPDH was used as the reference
gene. Results are themean ± 1 STDEVof three independent experiments performed in triplicate. *p value£0.05 and **p value£0.005 (Student’s t test).
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MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 2 9 5e3 0 8 307as a putative prognostic indicator for metastatic progression
in patients with lower grade tumours at diagnosis, an area
of unmet clinical need.5. Conflict of interests
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